Top Story

Majority of adverse events in clinical trials remain unpublished

September 30, 2016

A lower number and smaller range of adverse events were reported in published studies compared with those unpublished, according to data published in PLoS Medicine.

“We identified serious concerns about the substantial amount of unpublished adverse events data that may be difficult to access or ‘hidden’ from health care workers and members of the public,” Su Golder, PhD, in the Department of Health Sciences at the University of York in the United Kingdom, and colleagues wrote. “Incomplete reporting of adverse events within published studies was a consistent finding across all the methodological evaluations that we reviewed.”

Survey: Americans consider cancer nation's top health care challenge

September 30, 2016
Americans consider cancer the most significant health care challenge in the United States, according to results of the Mayo Clinic National Health Checkup survey. The…
At Issue

Cancer survivors with physical, psychological concerns benefit from team-based approach to care

September 30, 2016
Survivors of breast cancer have “a variety of concerns” following completion of treatment, according to Charles L. Shapiro, MD, of the Icahn School of

ALF, Bayer collaborate to elevate liver cancer awareness

September 30, 2016
October is Liver Cancer Awareness Month, and Bayer and the American Liver Foundation announced the third consecutive year of a shared initiative to draw attention to the…
Meeting News Coverage

ACA has improved cancer care, clinical trial access among Hispanics

September 30, 2016
The proportion of Hispanic women with breast cancer who presented at an NCI–designated cancer center and enrolled in a clinical trial significantly increased…
More News Headlines »
CME Video

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-Line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Meeting News Coverage

VIDEO: Atezolizumab, cobimetinib in combination demonstrate activity in colon cancer

September 7, 2016
More »

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Current Issues
View the Current Issue
HemOnc Today